Pfizer Initiates P-III RENOIR Trial of RSVpreF Vaccine for the Treatment of Respiratory Syncytial Virus
Shots:
- The company initiates a P-III RENOIR trial to evaluate RSVpreF vs PBO in 30-000 adults aged ≥60yrs. with RSV
- The 1EPs of the study is to evaluate the safety & efficacy for the prevention of mod. to sev. LRTI during the first RSV season
- In Nov’18- the vaccine has received FTD from FDA for the prevention of RSV-associated lower respiratory tract illness in infants by active immunization of pregnant women
| Ref: Pfizer | Image: Wall Street Journal
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com